May 2019 Stable angina is the most common clinically evident manifestation of coronary heart disease (CHD); it is present in almost half of all prevalent CHD cases. The aim of chronic medical…
No novel pharmacotherapeutics have entered the AD market in more than 15 years, despite a perennially full pipeline. However, the potential launches of the first disease-modifying therapies (DMTs)…
First-line treatment of chronic heart failure (CHF) usually involves an angiotensin-converting enzyme (ACE) inhibitor, an oral beta blocker, and an oral diuretic. The addition of a second- or third…
MARKET OUTLOOK Several effective anti-inflammatory agents and bronchodilators are available for controlling patients’ mild or moderate asthma. However, despite the market entry of LAMAs (e.g.,…
MARKET OUTLOOK Although TNF-alpha inhibitors remain the preferred choice for psoriatic arthritis (PsA) treatment following conventional DMARDs, the more recently introduced IL-17 inhibitors,…
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who the…
The treatment of multiple myeloma has advanced considerably in recent years with Celgene’s Revlimid and Janssen / Takeda Pharmaceutical’s Velcade remaining key cornerstones of treatment…
MARKET OUTLOOK Dyslipidemia is an important modifiable risk factor for CV disease and is primarily managed with statin therapy. Based on the positive CVOT data for certain nonstatin therapies,…
MARKET OUTLOOK Rheumatoid arthritis (RA) patients refractory to one or more TNF-α inhibitors are generally prescribed a non-TNF-targeted therapy (e.g., Bristol-Myers Squibb’s Orencia, Roche’…
MARKET OUTLOOK Multiple myeloma is an incurable hematological malignancy despite the availability of several treatment options. Resistance to therapy is the primary treatment challenge associated…
Obesity is arguably the most pressing public health issue in the United States. The prevalence of obesity is extremely high, and its chronic progression is associated with type 2 diabetes and…
DRG epidemiologists estimate that 40% of epilepsy patients experience generalized-onset seizures (GOS). The most commonly prescribed early-line treatments for GOS are older antiepileptic drugs (…
DRG epidemiologists estimate that 60% of epilepsy patients experience partial-onset seizures (POS), which aretypically the gateway indication for new antiepileptic drugs (AEDs). The most frequently…
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who the…
A comprehensive, quantitative understanding of patient progression through all stages of disease management and treatment is critical in both assessing a market opportunity within a therapeutic…